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Abstract
Antimicrobial resistance is a serious problem to solve especially in developing countries like India. Antibiotic use in
India increased several times since 2005. Many studies in India have reported inappropriate and overuse of antibiotics
which could be one of the possible reasons for increased antibiotic resistance in the country. This is an important and
urgent issue that mandates strict regulations regarding the rational use of antibiotics. World Health Organization (WHO)
has done a major revision to the essential medicines list which classiﬁes antibiotics into three categories (access, watch,
and reserve) to ensure the availability and correct use of antibiotics. Several countries started antimicrobial stewardship
programs to promote e appropriate use of antibiotics, reduce antibiotic resistance as well a ﬁnancial burden. Indian
government started a national action plan on antibiotic resistance in 2017 to promote the rational use of antibiotics but it
is still in its formative stage as all stewardship components are yet to be implemented. This review emphasizes the
importance and the need for implementing WHO's AWaRe strategy and antimicrobial stewardship to promote rational
antibiotic use in the country.
Keywords: Antibiotic consumption, Antibiotic resistance, National action plan on antimicrobial resistance, AWaRe
classiﬁcation, Antimicrobial stewardship

Key messages
Antimicrobial resistance is a serious problem to solve
for the public health authorities specially in developing countries like India. Conducting interventional
studies to implement the WHO AWaRe strategy and
antimicrobial stewardship program could be beneficial in promoting the rational use of antibiotics in
India.

1. Introduction

T

he development of antimicrobial resistance
has become a matter of great public health
concern [1]. Antimicrobial resistance is a serious
problem and worldwide deaths directly attributable

to antimicrobial resistance are 700,000 per year
which is further projected to increase to 10 million
by the year 2050 if current trends continue. The
estimated cumulative loss of economic output from
antimicrobial resistance by 2050 would amount to 20
to 35 trillion US dollars [2]. Antimicrobial resistance
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is a serious problem to solve for the public health
authorities at the global level, particularly in
developing countries like India. Data on studies
conducted in hospitals and communities in India
reveal an increased burden of antimicrobial resistance [3]. As per the report of the center for disease
control, in India there is an increase in the risk of
antibiotic resistance for commonly seen diseases of
public health concern (Table 1). Recently, NDM-1positive bacteria have also been reported resistant
[1]. The clinical impact of antibiotic resistance is
huge, with increased morbidity and mortality,
extended hospital stays, and increased costs of
health care [4,5].

2. Inappropriate use of antibiotics: a major
concern
One of the possible reasons for antibiotic resistance could be the inappropriate or overuse of antibiotics [6]. In 2015, an analysis of antibiotic use in
76 countries, reported that total worldwide antibiotic consumption was 35 billion DDDs, which was
an increase of 65% from 2000 [7]. India is one of the
world's largest antibiotics consumers [8]. Antibiotic
use in India became doubled between 2000 (3.2
Billion deﬁned daily doses) and 2015 (6.5 billion
deﬁned daily doses) [7]. Evidence suggested that
there is a high proportion of antibiotic use in the
private sector also. Studies from India reported that
in the private sector, expensive newer class antibiotic use was more as compared to older ones [9].
The relationship between antibiotic exposure and
antibiotic resistance is unclear on the population
and individual level [10,11]. WHO headquarters
developed a database for developing countries that
include quantitative information on antibiotic use in
primary care, which has been systematically
collected data from studies published between 1990
and 2007. Toof tal 679 studies from 97 countries were
identiﬁed of which 151 studies came from the SEA
(South East Asia) region. It was found that 50% of
viral upper respiratory tract infections are treated
unnecessarily with antibiotics, even though only

53% of pneumonia cases receive an appropriate
antibiotic; about 54% of acute diarrhea cases are
treated unnecessarily with antibiotics, while only
55% receive oral rehydration solution as suggested
in the treatment guidelines; and 40% of prescribed
antibiotics are under-dose [12]. Published community studies have reported that for diseases like
diarrhea and fever, which are primarily viral,
approximately 70% of patients in the healthcare facilities are given antibiotics [13]. In many countries
of the SEA Region, antibiotics are freely available
over the counter without prescription which is
against regulations [14]. Another study was done in
three Indian cities, and reported that the most
commonly prescribed antibiotic class in the community was ﬂuoroquinolones, often for coughs and
colds, which is entirely inappropriate [15]. The 2015
WHO multi-country survey revealed widespread
public misunderstanding about antibiotic usage and
resistance. The survey highlights for India are of
concern: Three quarters (75%) of respondents
thought incorrectly, that colds and ﬂu can be treated
with antibiotics; and only 58% knew that they
should stop the antibiotics only when the course is
completed as directed. More than three-quarters
(76%) of respondents reported taking antibiotics
within the past 6 months; 90% said they were prescribed or provided by a doctor or nurse [16].
Studies support that restricting misuse of antibiotics
reduces resistance [17]. An issue that needs to be
addressed in India is the regulation of the medical
sector, particularly in the prescription of medicines
[16].

3. India's National Action Plan on
Antimicrobial Resistance (NAP-AMR)
India needs to take active steps to overcome
antimicrobial resistance. All stakeholders within a
country and an area must take collective action to
achieve this goal [18]. The Indian government as
well as all healthcare stakeholders in India accepted
AMR (Antimicrobial Resistance) as a major issue to
be solved. India is coming forward to resolve this

Table 1. Drug resistance in common diseases of public health importance in India.
Disease

Resistant antibiotic

Percentage resistance

Cholera

Furazolindone
Cotrimoxazole
Nalidixic acid
Chloramphenicol, Ampicillin, and Cotrimoxazole
Fluroquinolones
Cotrimoxazole, Ciproﬂoxacin, and Tetracyclin
Penicillin
Ciproﬂoxacin

60e80%
60e80%
80e90%
30e50%
Up to 30%
50e100%
50e80%
20e80%

Enteric fever
Meningococcal infection
Gonococcal infection
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problem by implementing National Action Plan on
antimicrobial resistance and improving the use of
antibiotics by doctors, consumers, and health institutions [19]. Indian government implemented
National Action Plan on antimicrobial resistance
(NAP-AMR) in 2017 [20]. NAP-AMR emphasizes the
need for improving the knowledge of rational use of
antibiotics among various healthcare stakeholders
through monitoring and research activities [21]. The
plan set out ﬁve objectives i.e. to improve awareness
and understanding of antimicrobial resistance; to
strengthen surveillance and research; to reduce the
incidence of infection; to optimize the use of antimicrobials, and to ensure sustainable investment in
countering antimicrobial resistance [18]. Indian
Medical Association (IMA) also has launched four
campaigns for health care professionals to tackle
this public health hazard e ‘Jarrurat Bhi hai kya’,
'3A” means Avoid Antibiotic Abuse’, ‘use wisely not
widely' and ‘Think before ink”. Indian Council of
Medical Research (ICMR) has also promoted this
plan by implementing an anti-microbial stewardship program at 20 private and public hospitals in
country [22].

4. WHO AWaRe strategy against antimicrobial
resistance
The WHO's essential drug list includes a list of the
minimum medicines required for a basic health care
system. This list contains only those medicines
which are most effective, safe, and cost-effective for
the major priority of the public [23]. In 2017, WHO
experts have done major revision in the antibiotic
section of EML which is categorized antibiotics into
three categories i.e. Access, Watch, and Reserve. It
provides advice on which antibiotics to use to treat
common bacterial infections and which antibiotics
to save for severe diseases. It recognizes the
importance of optimizing antibiotic use and
reducing antibiotic resistance without access restriction. The purpose of this modiﬁcation is to
ensure that antibiotic is available when needed and
the correct antibiotic is prescribed for an appropriate infection. It should increase treatment effectiveness, minimize drug resistance development,
and should preserve the effectiveness of “last resort”
antibiotics. These changes support the WHO's
Global Action, which aims to overcome the development of drug resistance by ensuring the rational
use of antibiotics [23]. The three categories of antibiotics are as follows [24,25].
Access: This class of antibiotics includes those
which have very low potency to develop resistance.
These antibiotics are to be used as a ﬁrst or second
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choice for empiric treatment of most common infections and thus should be available at all times at
appropriate quality, dose, formulation, and price.
Watch: This class of antibiotics includes antibiotics
that were considered in general to have higher
toxicity concerns and resistance potential. This
group contains antibiotics which are advised to be
used as a ﬁrst or second choice for a small number
of infections. The use of these antibiotics has been
reduced adequately to avoid further development of
resistance.
Reserve: This category contains antibiotics that are
considered the “last resort” option and are only used
in the most severe infections when all other options
fail such as multidrug-resistant bacterial infections.
These antibiotics are the main goals of high-intensity national and international level programs
involving central monitoring and reporting to preserve their effectiveness. A complete list of Access,
Watch, and Reserve antibiotics is given in Table 2.
WHO suggested that the Access group of antibiotics should be available widely at all healthcare
institutions and at an affordable cost to control the
use of the other two groups of antibiotics. A recent
report on antibiotic sales data in India between 2007
and 2012 showed that the consumption of the Watch
group and Reserve group antibiotics is increasing
rapidly compared to the Access group [26]. The ﬁrst
global collaborative study based on the WHO
AWaRe approach was conducted on hospitalized
children. The study reported variation between
countries in the use of Access, Watch, and Reserve
antibiotics in children and neonates. In children,
Acto cess antibiotic use ranged from 7.8% in China
to 61.2% in The Gambia, and Watch antibiotic use
ranged from 23.0% in Finland to 77.3% in Iran [27].
In India, total systemic antibiotic sales increased
by 26% from 2056 million Units in 2007e08, to 2583
million in 2011e12. The increase was due to the
growth in sales of FDCs, which rose by 38%,
whereas sales of SDFs increased by 20%. By
2011e12, FDCs comprised 34% (872 million units),
and SDFs 66% (1711 million units), of total sales in
India [28]. As per WHO AWARe categories, FDC
antibiotics sales in India in 2011e12 include: 499
million units of access antibiotics, 367 million units
of watch group antibiotics, 3 million units of reserve
antibiotics, and 3 million units were included in
uncategorized antibiotics. Compared to 2007e08,
Key Access antibiotic sales had increased by 20%;
However, FDC sales with watch group or reserve
group antibiotics increased by 73% and 174%
respectively [29]. Indian healthcare authorities
should consider modifying the national EML based
on WHO EML in three categories (AWaRe) for
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Table 2. 2019 WHO AWaRe classiﬁcation of antibiotics.
Class

Antibiotics

ACCESS

Amikacin, Amoxicillin, Amoxicillin/clavulanic Acid, Ampicillin, Ampicillin/sulbactam, Bacampicillin, Benzathine
benzylpenicillin, Benzylpenicillin, Cefacetrile, Cefadroxil, Cefalexin, Cefalotin, Cefapirin, Cefatrizine, Cefazedone,
Cefazolin, Cefradine, Cefroxadine, Ceftezole, Chloramphenicol, Clindamycin, Clometocillin, Cloxacillin, Dicloxacillin, Doxycycline, Flucloxacillin, Gentamicin, Mecillinam, Metronidazole (IV), Metronidazole (oral), Nafcillin,
Nitrofurantoin, Oxacillin, Penamecillin, Phenoxymethylpenicillin, Pivampicillin, Pivmecillinam, Procaine benzylpenicillin, Spectinomycin, Sulfadiazine/trimethoprim, Sulfamethizole/trimethoprim, Sulfamethoxazole/trimethoprim,
Sulfametrole/trimethoprim, Sulfamoxole/trimethoprim, Sultamicillin, Tetracycline, Thiamphenicol, Trimethoprim
Arbekacin, Azithromycin, Azlocillin, Biapenem, Carbenicillin, Cefaclor, Cefamandole, Cefbuperazone, Cefcapene
pivoxil, Cefdinir, Cefditoren pivoxil, Cefepime, Cefetamet pivoxil, Ceﬁxime, Cefmenoxime, Cefmetazole, Cefminox,
Cefodizime, Cefonicid, Cefoperazone, Ceforanide, Cefoselis, Cefotaxime, Cefotetan, Cefotiam, Cefotiam hexetil,
Cefoxitin, Cefozopran, Cefpiramide, Cefpirome, Cefpodoxime proxetil, Cefprozil, Ceftazidime, Cefteram pivoxil,
Ceftibuten, Ceftizoxime, Ceftriaxone, Cefuroxime, Chlortetracycline, Ciproﬂoxacin, Clarithromycin, Clofoctol,
Delaﬂoxacin, Dibekacin, Dirithromycin, Doripenem, Enoxacin, Ertapenem, Erythromycin, Fleroxacin, Flomoxef,
Flumequine, Fosfomycin (oral), Fusidic Acid, Garenoxacin, Gatiﬂoxacin, Gemiﬂoxacin, Imipenem/cilastatin, Isepamicin, Josamycin, Kanamycin, Latamoxef, Levoﬂoxacin, Lincomycin, Lomeﬂoxacin, Lymecycline, Meropenem,
Metacycline, Mezlocillin, Micronomicin, Midecamycin, Minocycline (oral), Moxiﬂoxacin, Neomycin, Netilmicin,
Norﬂoxacin, Oﬂoxacin, Oleandomycin, Oxytetracycline, Panipenem, Pazuﬂoxacin, Peﬂoxacin, Pheneticillin, Piperacillin, Piperacillin/tazobactam, Pristinamycin, Pruliﬂoxacin, Ribostamycin, Rifabutin, Rifampicin, Rifamycin,
Rifaximin, Roxithromycin, Ruﬂoxacin, Sisomicin, Sitaﬂoxacin, Sparﬂoxacin, Spiramycin, Spiramycin/metronidazole,
Streptomycin, Sulbenicillin, Tebipenem, Teicoplanin, Telithromycin, Temocillin, Ticarcillin, Tobramycin, Tosuﬂoxacin, Vancomycin (IV), Vancomycin (oral)
Aztreonam, Ceftaroline fosamil, Ceftazidime-avibactam, Ceftobiprole medocaril, Ceftolozane-tazobactam, Colistin,
Dalbavancin, Dalfopristin-quinupristin, Daptomycin, Eravacycline, Faropenem, Fosfomycin (IV), Linezolid, Meropenem-vaborbactam, Minocycline (IV), Omadacycline, Oritavancin, Plazomicin, Polymyxin B, Tedizolid, Telavancin, Tigecycline

WATCH

RESERVE

This list was adapted from World Health Organization.

antibiotics. Actions should be taken by regulators
and policymakers to improve the availability and
use of access antibiotic groups, as well as a reduction and rational use of watch and reserve antibiotics in both the public and private sectors.

5. Antimicrobial stewardship
AMS (Antimicrobial Stewardship) refers to “coordinated interventions designed to improve and
measure the appropriate use of antimicrobials by
promoting the selection of the optimal antimicrobial
drug regimen, dose, duration of therapy, and route
of administration’’ [30]. These programs are beneﬁcial in reducing treatment failures, reducing hospital-acquired infections and reducing antibiotic
resistance while being ﬁnancially beneﬁcial for
hospital [31]. There are “4 Ds” required for optimal
antimicrobial prescribing: drug, dose, duration, and
de-escalation. Ideally, the prescriber selects the
right drug (e.g. most narrow spectrum), at the right
dose (e.g. adjusted for patient renal function), for the
right duration (e.g. shortest to successfully treat
infection), and considers de-escalation whenever
possible (e.g. narrow-spectrum based on culture
results). A ﬁfth “D” of stewardship, which is perhaps
most critical in the context of emergency care, is
diagnosis. Prescribing of antibiotics for inappropriate diagnoses (i.e. non-responsive conditions) is

prevalent in the emergency department for all
common infection types. This includes upper respiratory tract infections (e.g. bronchitis, sinusitis),
urinary tract infections (e.g. asymptomatic bacteriuria), and skin and soft tissue infections (e.g.
“pseudocellulitis”) [32]. In general, AMS teams
should monitor antibiotic use in the hospital to ﬁnd
out the most common misused antibiotics and
multidrug-resistance organisms and should decide
on appropriate interventions to improve this problem [33].

6. Importance of antimicrobial stewardship
program
The Antimicrobial Stewardship Program (AMSP)
has shown obvious beneﬁts in reducing the rate of
improper use of antibiotics [34e36]. There is enough
evidence to prove that AMSP is useful to promote
rational antibiotic use and reduce the cost of therapy. Various countries have implemented AMSP
and reported a reduction in antimicrobial use
associated with signiﬁcant cost savings. Evidence
suggested that implementing AMSP resulted in
reducing the cost of antibiotics expenditure by 3$
million over 3 years [37]. A systematic review and
meta-analysis of 26 studies to determine the efﬁcacy
of hospital-based antimicrobial stewardship showed
signiﬁcant improvement in clinical and economic
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outcomes and signiﬁcant reductions in antimicrobial consumption as well as cost in the critical care
setting [38]. Surveys conducted in different hospitals
in Australia to monitor the effectiveness of AMSP
found that comprehensive AMS programs resulted
in an overall reduction in antimicrobial use by
22e36% and substantial pharmacy cost savings.
Successful implementation of AMS programs has
been shown to improve the appropriateness of
antimicrobial use and thereby reduce institutional
resistance rates, morbidity, mortality, and healthcare costs [39]. Implementing AMSP has proven to
be effective in reducing C. Difﬁcile in hospitals [40].
Studies suggested that AMSP was found to be
effective in rationalizing the use of antibiotics used
in surgical prophylaxis and also helped clinicians in
optimizing the dose in patients with impaired renal
functions [41]. One study reported that implementing AMS resulted in a 70% increase in infections
cure and an 80% decrease in treatment failure [42].
A questionnaire-based survey was conducted by
United States Centres for Disease Control and Prevention ‘Core Elements of Hospital Antibiotic
Stewardship Programs' to monitor the status and
possible problems in implementing antimicrobial
stewardship (AMS) in 116 Grade-A tertiary hospitals in China. Reported signiﬁcant improvement in
AMS, mainly including the antibiotic consumption
index [43]. A systematic review was conducted to
assess the effectiveness of antibiotic stewardship
interventions in hospitals in low-middle-income
countries. This included 27 studies from 11 middleincome and two low-income countries that reported
positive effects of hospital antibiotic stewardship
interventions in many countries [44].

7. Antimicrobial stewardship program: Indian
scenario
Implementation of AMSP in India is still in its
formative stage as all the stewardship components
are yet to be fully implemented in the country. A
survey conducted in India to monitor the implementation of all components of the AMSP showed
that only 35% (6 studies) of the 17 studies involved
were based on the entire AMSP implementation,
while other studies included at least one of the
AMSP Implementation components [45]. Another
survey carried out about AMSP components
implementation and outcome by ICMR in 2013
among 20 tertiary Health care institutions reported
that only 40 percent of institutions had AMSP
written documents, 65 percent had AMAs prescription guidelines and 75 percent had HIS
(Healthcare Infection Society) guidelines [46]. AMSP
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program is not fully implemented in India, especially at the primary care level. There is a need of
conducting an educational program for various
health care professionals regarding AMS and also a
need to promote research to implement AMS in
both public as well as private health facilities.

8. Barriers to implementing AMS and WHO
AWaRe strategy
Many factors can act as a barrier to the successful
implementation of AMSP and the WHO Aware
Strategy. One of the important factors is the limited
availability of antimicrobials. Various surveys conducted in different parts of India reported a lack of
access to essential medicines including antimicrobials, especially in the public health sector [47]. Lack
of access to antimicrobials has been reported in
other LMICs as well [48]. A recent report analyzed
antibiotic sales data in India between 2007 and 2012
which showed that the consumption of Watch group
and Reserve group antibiotics is increasing rapidly
when compared to the Access group of antibiotics
[49]. Therefore ensuring the availability of quality
antimicrobials is important for the successful
implementation of AMSP and AWaRe strategy. Indian authorities should consider revising the National EML and adopting the WHO EML for
antibiotics in three categories (AWaRe) to optimize
the use of antimicrobials. Another important factor
is limited diagnostic facilities. The lack of diagnostic
facilities has been attributed to the overuse of antibiotics [50]. Improved laboratory capacity and
structured surveillance techniques to create an
antibiogram are required in India. Resistance to
changing current practices can also play role in the
failure of AMSP. As resistance rates differ in
different countries, this could lead to inappropriate
use of antimicrobials in different clinical situations.
The lack of updated guidelines regarding antimicrobial prescribing may lead to failure of AMSP.
Therefore Infectious Disease Society of America
(IDSA) is recommended to create guidelines based
on local resistance patterns for successful utilization
of antimicrobials [51]. A study conducted in Kerala,
India to examine key barriers and facilitators of
implementing ASP in a tertiary hospital using the
SEIPS (System Engineering Initiative for Patient
Safety) model found that inadequate physical visibility of stewardship activities, limited access to
clinical pharmacists, high physician workload and
high antibiotic use in the community were major
barriers to effective ASP implementation [52].
India needs trained pharmacists and microbiologists to meet the need for antibiotic stewardship and
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infection control across different institutions and
hospitals throughout the country. This is essential to
improve the implementation activities by building
and strengthening components such as the use of
information technology in monitoring and surveillance, use of antibiotic cycling, sensitizing staff, and
broadening the role of different staff members to
develop an effective program in the nation that
meets the goals of NAP-AMR. Health care professionals, healthcare authorities, and other stakeholders should move forward for a common goal of
antimicrobial stewardship and should work to
assess ground realities in antibiotic use and hospital
infections, as well as a collaborative approach,
should be developed to reduce the infection as well
as antimicrobial resistance.

9. Conclusion
Studies reported that the implementation of an
antimicrobial stewardship program is beneﬁcial in
promoting the rational use of antibiotics. India
needs to implement a stewardship program and use
antibiotics according to the AWaRe (Access, Watch,
and Reserve) classiﬁcation in both public and private health facilities. A collaborative approach by all
health care providers and government towards
stewardship programs is necessary to make India's
National Action Plan on Antimicrobial Resistance
(NAP-AMR) successful. Conducting interventional
studies on antibiotic use in health facilities and
creating awareness in public about the harmful effect of self-medication could help to save antibiotics
for present and future generations.
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